The approval in the second-line EGFR- and MET-altered setting was based on results from the SACHI trial, which compared Orpathys and Tagrisso against chemo.

The company is developing treatments for autism and substance use disorders tailored to patient subgroups identified by clinico-genomic signatures.

NEW YORK – Ionis Pharmaceuticals has treated the first patient in a Phase III clinical trial evaluating the efficacy and safety of its investigational antisense oligonucleotide (ASO) therapy for ...

For selected applicants, the agency plans to cut review times down to one to two months and provide "tumor board-style" ...

UCLA-led investigators say additional research is needed into why guideline-recommended genetic testing remains low among ...

The firm will take a different reimbursement strategy for the test than its prior owner Biocept, which stopped selling it after filing for bankruptcy in 2023.

The agency will allow BMS to discontinue REMS programs for both therapies and reduce certain patient monitoring requirements.

NEW YORK – Artera said this week that it has received a laboratory permit from New York state allowing it to offer its artificial intelligence-based prostate cancer test to patients there. The ...

The company said the therapy is the first allogenic therapy developed with its Tmod technology to be tested in humans.

A legislative ban on pharma ads, a tool for companies to amplify messaging on drugs, including for precision medicines, is sure to face legal challenges, experts say.

NEW YORK – Philochem, a Swiss subsidiary of Philogen, announced this week that it will license worldwide rights for its lead radiopharmaceutical to RayzeBio, which is owned by Bristol Myers Squibb.